Idorsia Ltd. · SIX:IDIA
Idorsia — Investor Presentation (March 2024)
149 slides from Idorsia's investor presentation, March 2024
Slide 1: Idorsia – Reaching out for more
Idorsia – Reaching out for more
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: The purpose of Idorsia
The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more Opportunities, and we want to transform the horizon of therapeutic options. 3 Idorsia - Reaching out for more | March 2024
Slide 4: Our company history and leadership
Our company history and leadership Actelion, founded in 1997 by four researchers, Jean-Paul Clozel, MD (CEO) and Martine Clozel, MD changed the lives of thousands of patients living (CSO) bring with them not only drug discovery pedigree with pulmonary arterial hypertension as researchers but experie
Slide 5: A start-up like no other
A start-up like no other Idorsia has the ideal constellation for bringing successful medicines to patient >10 >20-year Idorsia and partner-led assets in our portfolio Heritage of drug discovery >800 Highly qualified Global professionals Commercial operations in Europe and North America 5 Idorsia - R
Slide 6: TRYVIO (aprocitentan) 12.5 mg approved by the US FDA in March 2024
TRYVIO (aprocitentan) 12.5 mg approved by the US FDA in March 2024 Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 6 Idorsia - Reaching out for more | March 2024
Slide 7: Collaboration and license agreement with Viatris
Collaboration and license agreement with Viatris for selatogrel and cenerimod • Combines Viatris’ financial strength and worldwide operational infrastructure with Idorsia’s proven, highly productive drug development team and innovative engine. • Idorsia received an upfront payment of USD 350 million
Slide 8: Adapting the company to create sustainable value
Adapting the company to create sustainable value Adapting global Adapting Adapting Raise presence workforce portfolio cash Sale of Idorsia Reduction at all Stopping or Extending cash Japan and South levels of the partnering R&D runway beyond Korea company assets Q1 2024 8 Idorsia - Reaching out for
Slide 9: CHF 400 million deal with Sosei Heptares
CHF 400 million deal with SALE of PIVLAZ (clazosentan) Daridorexant Option Idorsia's assignment of co-exclusive license to exclusive affiliates in Roche's license in the Territory and license lucerastat Japan and Korea in the Territory assignment of all and cenerimod potential milestones in the Terr
Slide 10: Our Strategic Priorities
Our Strategic Priorities Our mid-term key priorities to 2 Successfully launch our new products achieve long-term 3 Bring Idorsia to success: sustainable profitability 1 Advance late- stage pipeline 4 Fuel our pipeline with new discoveries 5 Utilize state-of-the-art technologies to drive innovation 1
Slide 11: Our commercial reach
Our commercial reach Europe Allschwil, Switzerland Paris, France Munich, Germany Milan, Italy Madrid, Spain Stockholm, Sweden London, United Kingdom North America Radnor, Pennsylvania USA Montreal, Canada 11 Idorsia - Reaching out for more | March 2024
Slide 12: Our pioneering therapies
Our pioneering therapies With a broad, diversified and balanced development pipeline, Idorsia is well positioned to develop new and differentiated products in multiple therapeutic areas: • CNS • Cardiovascular • Immunological disorders • Orphan diseases The company also has a vaccine platform discov
Slide 13: Idorsia-led portfolio
Idorsia-led portfolio Compound / Mechanism of action / Target indication Phase 1 Phase 2 Phase 3 Registration Commercially available QUVIVIQ (daridorexant) Dual orexin receptor antagonist Commercially available as QUVIVIQ in the US, Germany, Italy, Switzerland, Spain, UK, Canada and Austria; approve
Slide 14: Partner-led portfolio
Partner-led portfolio Compound / Mechanism of action / Target indication Partner Phase 1 Phase 2 Phase 3 Registration Commercially available Daridorexant Dual orexin receptor antagonist Sosei Heptares License to develop and commercialize for Asia Pacific (ex-China) Insomnia NDA submitted in Japan. D
Slide 15: Innovation from bench to bedside
Innovation from bench to bedside Leveraging state-of- the-art technologies throughout the lifecycle Drug Discovery of our compounds • Artificial intelligence • Computer modelling Commercialization Clinical Development • Digital & Social Media • Patient reported • Advanced analytics outcome measures
Slide 16: Find a comprehensive description of our pipeline assets
Find a comprehensive description of our pipeline assets as follows: 1 Daridorexant Slide 17 2 Aprocitentan Slide 65 3 Lucerastat Slide 96 4 Early-stage assets Slide 125 16 Idorsia - Reaching out for more | March 2024
Slide 17: Daridorexant in insomnia
Daridorexant in insomnia Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, and the UK under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union, and Canada. 17 Idorsia - Reaching out for more | March 2024
Slide 18: Insomnia: A disease of the night and the day
Insomnia: A disease of the night and the day High unmet need for effective, safe medications to treat insomnia • Combination of difficulty obtaining sufficient Difficulty sleep and dissatisfaction with sleep combined staying with a significant negative impact on daytime asleep functioning Difficulty
Slide 19: Insomnia and the importance of sleep
Insomnia and the importance of sleep Sleep is an essential pillar for good Therefore, without adequate, Insomnia disorder, the most common sleep- physical and mental health to ensure quality sleep, one can face many wake disorder, is defined by difficulties in optimal functioning throughout the day.
Slide 20: How is insomnia treated, what are the limitations?
How is insomnia treated, what are the limitations? Sleep hygiene Cognitive Pharmacological therapy • Active behavioral therapy • Many have significant limitations patient • Recommended first- • Insufficient acute effect: participation line therapy but lack of sustained effect through the night requi
Slide 21: Prevalence and impact of insomnia across Europe
Prevalence and impact of insomnia across Europe With respect to global Across Europe, CID is associated to burden, insomnia is ranked approximately half of all 11/18 days of absenteeism by the World Health adults are expected to and Organization as the experience some insomnia 39-45 days of presente
Slide 22: Hidden economic burden of CID
Hidden economic burden of CID (working-age adults) Estimated “hidden” annual financial Who’s affected? burden across working-age % of adults suffering from CID Number of adults population suffering from CID 7.6% 18.6 million €92bn 8.8% 2.2 million Can$ 10.7bn 7.7% 16.6 million $127.1bn 22 Idorsia -
Slide 23: The US insomnia market is large and dissatisfied
The US insomnia market is large, highly dissatisfied, and ripe for disruption Who’s affected? Dissatisfaction What are the costs? ~25M In a recent poll of 1001 Americans who struggle $100B+ Total insomnia with sleep Insomnia related costs patients (~10% of US adults) 70% per year alone in the US say
Slide 24: High unmet need in EU insomnia market
High unmet need in EU insomnia market Estimated insomnia market volume*, standard units, millions Estimated 788 771 volume per 11.8 10.7 capita** 671 3'029 2'668 478 320 DE IT FR ES UK EU5 US Anti-depressants Anti-histamines Benzos Melatonin SR Z-drugs DORAs Source: IQVIA MIDAS EU5 – MAT/July 2022;
Slide 25: The science of sleep
The science of sleep Some therapies may increase somnolence and impair functioning. These attributes suggest current Healthy wake and sleep states therapies are limited in their ability to optimally treat are governed by distinct wake people with insomnia, particularly elderly patients. and sleep si
Slide 26: The orexin system and regulation of wakefulness
The orexin system is crucial for the regulation of wakefulness Orexin stimulates orexin many wake-promoting pathways Dopamine (VTA) Histamine Acetylcholine (LDT, PPT) (TMN) LHA / PH Orexin Serotonin (raphe) LC OX1R Norepinephrine (LC) TMN OX2R Raphe OX1R and OX2R LTD / PPT OX1R and OX2R VTA OX1R and
Slide 27: Daridorexant in insomnia
Daridorexant in insomnia Rationale • There remains a need for effective and safe treatments for insomnia Daridorexant • Accumulating evidence for the role of the orexin (OX) system to regulate wake drive • a potent and selective dual orexin has led to the development of new receptor antagonist (DORA
Slide 28: Different by design – next generation DORA
Different by design – next generation DORA Optimized pharmacokinetic profile Entry into man studies Plasma 1000 25 mg concentrations (ng/ml) 800 • Fast absorption • Optimal half-life (8 h) 600 • No accumulation over time • No active metabolites 400 200 0 0 24 48 72 96 120 144 168 Time (h) Daridorexa
Slide 29: Fast and time limited pharmacodynamic effect
Fast and time limited pharmacodynamic effect Entry into man studies Speed of eye 25 mg movements (degree/sec) Adult Healthy Volunteer – Daytime dosing Elderly Healthy Volunteer – Daytime dosing Time (h) Person performing eye movement test Daridorexant is available in the US, Germany, Italy, Spain, S
Slide 30: No pharmacodynamic effect on next morning
No pharmacodynamic effect on next morning Entry into man studies Karolinska Sleepiness Placebo 25 mg Scale Score 9 Very sleepy 8 7 Sleepy, but no effort keeping awake 6 Neither alert nor 5 sleepy 4 Alert, 3 normal level 2 1 Very alert Time after first dose (h) – measures 8 hours after dosing Daridor
Slide 31: Daridorexant registration program
Daridorexant registration program Robust program in adult and elderly insomnia patients Phase 3 program Following completion of Phase 2 studies, two similar pivotal studies of 3-month duration in moderate and severe insomnia Efficacy • Objective and subject sleep parameters (onset and maintenance) b
Slide 32: Study objectives
Study objectives 1st study, 50, 25 mg; 2nd study, 25, 10 mg Phase 3 program Primary objective • To evaluate the efficacy of daridorexant on objective sleep parameters in patients with insomnia. Secondary objective • To evaluate the efficacy of daridorexant on subjective sleep parameters and daytime
Slide 33: Objective sleep assessments
Objective sleep assessments Repeated polysomnography recordings in a sleep lab in all patients Phase 3 program • Assess insomnia objectively • Ensure well-characterized insomnia patients are randomized Sensors • Establish solid baseline during placebo run-in measure brain activity, eye • Measure pri
Slide 34: Primary endpoint: Wake after sleep onset (WASO)
1o endpoint: Wake after sleep onset (WASO) A measure of sleep maintenance 120 placebo 25 mg 50 mg Daridorexant 25 mg and 50 mg significantly improved WASO Mean of observed values (min) 100 p<0.0001 compared to placebo at 80 p<0.0001 months 1 and 3 60 LSM change from baseline (95% CI) p<0.0001 p<0.00
Slide 35: Primary endpoint: Latency to persistent sleep (LPS)
1o endpoint: Latency to persistent sleep (LPS) A measure of sleep onset 80 placebo 25 mg 50 mg Daridorexant 25 mg and 50 mg significantly improved LPS Mean of observed values (min) 60 compared to placebo at months 1 and 3 40 P=0.0005 p=0.0015 LSM change from baseline (95% CI) Month 1 Month 3 p<0.000
Slide 36: Sleep diary questionnaire (SDQ)
Sleep diary questionnaire (SDQ) Daily recording Morning questionnaire Evening questionnaire • 10 questions related to medication, • 2 questions related to napping quantification of sleep, awakenings • 2 visual analog scales related to • 3 visual analog scales related to alertness and ability to perf
Slide 37: Secondary endpoint: Subjective Total Sleep Time
2o endpoint: Subjective Total Sleep Time (sTST) A measure of how the patient think they slept 400 placebo 25 mg 50 mg Daridorexant 25 mg and 50 mg p<0.0001 significantly improved sTST p<0.0001 p=0.033 compared to placebo at Mean of observed values (min) 350 p=0.0013 months 1 and 3 LSM change from ba
Slide 38: Subjective assessment of daytime functioning
Subjective assessment of daytime functioning Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Measures Items are ranked on a numeric rating scale from 0-10 Item 1. How clear-headed did you feel today? Item 2. How well were you able to concentrate today? Item 3. How forgetful did you feel
Slide 39: Secondary endpoint: IDSIQ sleepiness domain
2o endpoint: IDSIQ sleepiness domain How energetic did you feel today? How mentally tired did you feel today? A measure of daytime functioning How physically tired did you feel today? How sleepy did you feel today? 24 placebo 25 mg 50 mg Daridorexant 50 mg significantly Mean of observed value (score
Slide 40: Exploratory endpoints: IDSIQ other scores
Exploratory endpoints: IDSIQ other scores A measure of daytime functioning placebo 25 mg 50 mg 35 80 22 Mood domain Alert/cognition domain Total Mean of observed value (score) 20 30 70 18 16 60 25 14 12 20 50 0 0 0 Baseline Month 1 Month 3 Baseline Month 1 Month 3 Baseline Month 1 Month 3 IDSIQ mood
Slide 41: Adverse events
Adverse events In the safety analysis population (n=1847) Study 1 Study 2 Dari 50 mg Dari 25 mg Placebo Dari 25 mg Dari 10 mg Placebo (n = 308) (n = 310) (n = 309) (n = 308) (n = 306) (n = 306) Participants with ≥1 adverse event* 116 (38%) 117 (38%) 105 (34%) 121 (39%) 117 (38%) 100 (33%) Adverse ev
Slide 42: Adjudicated adverse events
Adjudicated adverse events In the safety analysis population (n=1847) Study 1 Study 2 Dari 50 mg Dari 25 mg Placebo Dari 25 mg Dari 10 mg Placebo (n = 308) (n = 310) (n = 309) (n = 308) (n = 306) (n = 306) Adjudicated adverse events† Excessive daytime sleepiness 1 (<1%) 2 (1%) 1 (<1%) 4 (1%) 1 (<1%)
Slide 43: Further safety observations
Further safety observations No adverse events No withdrawal During the placebo run-out suggested that period, WASO and LPS symptoms were were numerically lower, drug misuse observed during the and mean self-reported might have placebo run-out period, total sleep time was higher occurred as assessed
Slide 44: The daridorexant clinical program provides a wealth of evidence
The daridorexant clinical program provides a wealth of evidence Comprehensive sleep Daytime functioning perceived Documented safety efficacy perceived by by patients (50 mg) • A low overall incidence of patients (25 mg & 50 mg) • Improved sleepiness adverse events (AE), • Fall asleep faster • Consis
Slide 45: On track to become a global brand
On track to become a global brand Launched in Canada Licensed to Simcere Approved by the European in China Medicines Agency and MHRA Launched in the US Launched in Germany, Italy, Switzerland, Spain, the UK, Licensed to Sosei Austria, and France Heptares in Japan Daridorexant is available in the US,
Slide 46: Collaboration with Syneos Health
Collaboration with Syneos Health Commercialization partner to launch daridorexant in the US, Europe, and Canada • Syneos Health selected as commercialization partner in order to effectively reach the primary care market, which accounts for a large volume of insomnia prescriptions, in the US, Europe,
Slide 47: License agreements with Sosei Heptares & Mochida
License agreements with Sosei Heptares & Mochida Sosei Heptares Co-exclusive license granted to Sosei Heptares for daridorexant in Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam Mochida Supply, c
Slide 48: License agreement with Simcere
License agreement with Simcere Development and commercialization of daridorexant in the Greater China region • Simcere has an exclusive right to develop and commercialize daridorexant in the Greater China region (Mainland China, Hong Kong, and Macau), one of the world's largest pharmaceutical market
Slide 49: QUVIVIQ launched in the US in May 2022
QUVIVIQ® (daridorexant) launched in the US in May 2022 Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK and Canada under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union. 49 Idorsia - Reaching out for more | March 2024
Slide 50: Educational campaigns to prime the US market
Educational campaigns to prime the US market The Alliance for Sleep Seize the Night & Day Wake up America The Quest for Sleep Sleep Survey Top sleep experts drive Partnering with Jennifer Consumer and HCP Documentary Film using education, awareness and Aniston to drive survey to reveal views and sto
Slide 51: QUVIVIQ US launch
QUVIVIQ US launch >125K >300K >35K patients prescriptions prescribers treated dispensed Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK and Canada under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union. 51 Idorsia - Reaching o
Slide 52: Demand and payer coverage enable conversion to paid scripts
Demand and payer coverage enable conversion to paid scripts Revenue Inflection points ahead Q1 2024 Key Developments in the past CVS NDC Block Q4 2023 Removed ESI National Sep 2023 Formulary “Show Demand” for Payer Coverage Medicare Part D CVS – Parity Access Access anticipated Q3 2023 to other DORA
Slide 53: Supporting patient access and generating demand
Supporting patient access and generating demand CHF 15 million net sales in 9M 2023* *net sales do not reflect the volume of prescriptions dispensed due to patient assistance and coupon programs Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK and Canada under the trad
Slide 54: QUVIVIQ demand with increasing volume from retail
QUVIVIQ demand with increasing volume coming from retail QUVIVIQ Quarterly TRxs by Strength QUVIVIQ Quarterly TRxs by Source 80'000 25mg 50mg Total QUVIVIQ VitaCare IQVIA +23% +1% 70'000 60'000 +40% 50'000 +80% 74% 76% 40'000 72% 30'000 71% 20'000 72% 10'000 26% 28% 24% 29% 28% 0 2Q22 3Q22 4Q22 1Q23
Slide 55: Payer wins accelerate conversion to paid scripts
Payer wins accelerate conversion to paid scripts Key payer wins for QUVIVIQ Commercial Preferred Commercial Covered 23.1M lives1 22.2 MM Lives 1 Medicare Part D Non-Preferred Commercial Preferred 10.3 MM Lives 1 8.8 MM Lives 1 Commercial Preferred 5.0 MM Lives 1 Source: MMIT January 2, 2024 Daridore
Slide 56: Payer coverage and percentage of paid claims
Payer coverage and percentage of paid claims Idorsia Paid vs Payer Paid prescription Mix 100% 7% 12% 13% 16% 16% 14% 90% 18% 17% 18% 18% 18% 17% 17% 17% 18% 17% 18% 18% 18% 80% 70% 24% 24% 22% 43% 42% 60% 48% 46% 44% 53% 50% 54% 51% 81% 58% 58% 57% 50% 74% 69% 61% 40% 30% 57% 58% 59% 20% 41% 44% 35%
Slide 57: Scheduling under discussion
Scheduling under discussion Citizen’s Petition The FDA and DEA have acknowledged our Citizen Petition requesting de- scheduling the DORA class of medicines, and the process to analyze and examine the request seems to be moving forward Daridorexant is available in the US, Germany, Italy, Spain, Switz
Slide 58: Streamlined US operations for 2024
“We have streamlined the US operations for 2024 with the mindset ‘Achieving more with less’. For example, our dynamic digital marketing campaign is the #1 driver of traffic to the QUVIVIQ website so it will replace DTC TV commercials realizing substantial cost savings.” Tosh Butt President Idorsia U
Slide 59: Excitement about QUVIVIQ in Europe
Excitement about QUVIVIQ in Europe How likely would you be to prescribe How likely would you be to ask QUVIVIQ to your insomnia patients? your HCP about QUVIVIQ? 23% 37% HCPs Patients likely to 91% 41% likely to 85% prescribe ask about 29% 19% 27% Source: Idorsia market research in EU5 (n=1200); 202
Slide 60: QUVIVIQ: first DORA in Europe
QUVIVIQ: first DORA in Europe • Launched in Nov 2022 • Launched in Oct 2023 • “ASMR IV – SMR Moderate” recognizing the added value • 4-week limitation (Anlage III • NICE positive recommendation over available treatments exemption) lifted Nov 2023 • Unrestricted reimbursed • Price agreement with CEPS
Slide 61: Demand is growing in Europe
Demand is growing in Europe Quarterly standard units 603K >45’000 445K patient months 314K of treatment since launch 1Q 2Q 3Q Source: 100% sales record from wholesaler to pharmacy – IQVIA Midas Jan-Aug 2023, Sep estimated from internal sales Daridorexant is available in the US, Germany, Italy, Spain
Slide 62: QUVIVIQ net sales 9M 2023
QUVIVIQ (daridorexant) CHF 20.2 million net sales in 9M 2023* *in the US, Germany, Italy, Spain, and Switzerland; US net sales do not reflect the volume of prescriptions dispensed due to patient assistance and coupon programs Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, t
Slide 63: The European Insomnia Guideline 2023
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 “The introduction of DORAs has probably been the most significant recent development in the pharmacological treatment of insomnia...” Updates are being pulled through to local guidelines – already launched in
Slide 64: More sleep – over 11 million tablets dispensed
More sleep – over 11 million tablets dispensed to help better nights and days Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK and Canada under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union. 64 Idorsia - Reaching out for mor
Slide 65: Aprocitentan in systemic hypertension
Aprocitentan in systemic hypertension Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 65 Idorsia - Reaching out for more | March 2024
Slide 66: Quote on uncontrolled blood pressure
“Today, there are millions of Americans whose blood pressure is not well-controlled despite existing therapy. This is a major public health issue leading to a high incidence of cardiovascular events.” Jean-Paul Clozel Chief Executive Officer 66 Idorsia - Reaching out for more | March 2024
Slide 67: TRYVIO (aprocitentan) approved by the US FDA
TRYVIO (aprocitentan) 12.5 mg approved by the US FDA Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 67 Idorsia - Reaching out for more | March 2024
Slide 68: A unique compound with unique data
A unique compound with unique data Studied in patients 2 with well-defined resistant hypertension Inclusive study with 3 severe and fragile New pathophysiologic patient population 1 pathway in hypertension First study to 4 demonstrate durability of antihypertensive effect Outstanding 5 evidenced-bas
Slide 69: Quote on endothelin pathway selection
“Since the endothelin pathway was not yet tackled, we selected aprocitentan, an endothelin receptor antagonist with the ideal properties for use with patients whose hypertension is not adequately controlled with other antihypertensives.” Martine Clozel Chief Scientific Officer Aprocitentan is only a
Slide 70: First anti-hypertensive therapy in almost 40 years on a new pathway
The first anti-hypertensive therapy in almost 40 years which works on a new physiological pathway Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 70 Idorsia - Reaching out for m
Slide 71: Targeting a new pathway in hypertension
Targeting a new pathway Angiotensinogen in hypertension converted to Renin Endothelin Pathway Angiotensin I ACE converted to RAAS Pathway Endothelin 1 Angiotensin II binds to Vasoconstriction, TRYVIO ETA / B receptors hypertrophy AT1 receptor and remodeling (Angiotensin II Type 1) Aldosterone genera
Slide 72: >30 years of researching the endothelin system
>30 years of researching the endothelin system 1988 Endothelin-1 identified 2024 TRYVIO 1990 2022 (aprocitentan) ETA and ETB receptors Aprocitentan – approved by 1998 positive Phase 3 US FDA identified First evidence of 2007 in resistant 1993 dual ERA effect in Failed attempt hypertension hypertensi
Slide 73: Aprocitentan selected for its ideal properties
Aprocitentan selected for its ideal properties Orally-active, potent dual ETA and ETB receptor antagonist Low potential for drug-drug Synergistic effect with interaction other antihypertensive drugs (RAAS blockers) in animal models Phase 2 study shows blood pressure Demonstrated efficacy on blood pr
Slide 74: Quote on TRYVIO effect across endpoints
“TRYVIO demonstrated a clear and consistent effect across all endpoints of blood pressure measurement and in key sub-populations.” Alberto Gimona Head of Global Clinical Development Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Mark
Slide 75: PRECISION investigated durability of BP reduction
PRECISION investigated durability of BP reduction Selection of patients with uncontrolled hypertension on existing therapy Efficacy and safety of aprocitentan over 48 weeks confirmation Up to 8 weeks 4 weeks 4 weeks 4 weeks 32 weeks 12 weeks 30 days Screening Screening Run-in Part I Part II Part III
Slide 76: Frail population with multiple co-morbidities
Frail population with multiple co-morbidities Total: N = 730 [n (%)] Age (years) Antihypertensive therapies# Medical history Mean (SD) 61.7 (10.6) 3 269 (36.8) Diabetes mellitus 395 (54.1) 18 to <65 409 (56.0) 4 337 (46.2) Congestive heart 143 (19.6) 65 - <75 249 (34.1) ≥5 123 (16.8) failure ≥75 72
Slide 77: Disease burden when hypertension is uncontrolled
Disease burden when hypertension is uncontrolled 95% “Increased risk of certain health 88% Higher incidence of major cardiovascular events outcomes compared to those with controlled essential hypertension” REACH Registry n = 53,530 57% 44% 30% 23% Medication usage: Peripheral All-cause Coronary Stro
Slide 78: Significant and sustained BP reduction
Significant and sustained BP reduction Absolute BP reduction of 15 mmHg Primary endpoint Key secondary endpoint 12.5 mg vs placebo: -3.8 mmHg, P=0.0042 25 mg vs placebo: - 5.8 mmHg P<0.0001 25 mg vs placebo: - 3.7 mmHg, P=0.0046 Triple combination: single pill ARB (valsartan), CCB (amlodipine) , diu
Slide 79: USPI Highlights: Indication and Usage
USPI Highlights: Indication and Usage Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 79 Idorsia - Reaching out for more | March 2024
Slide 80: Reduction in BP will prevent CV events
Reduction in BP will prevent CV events 16-mmHg (uAOBPM) reduction in SBP vs baseline would avoid approximately 70 CV events per 1000 patients over the following 5 years Cardiovascular events avoided per 1000 Patients at risk NB: There are no controlled trials of cardiovascular demonstrating reductio
Slide 81: USPI Highlights: Dosage and Administration
USPI Highlights: Dosage and Administration USPI Section 14: Clinical Studies TRYVIO long-term sustained effect Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 81 Idorsia - Reach
Slide 82: USPI Section 14: Clinical Studies
USPI Section 14: Clinical Studies TRYVIO consistent effect in subgroups and across measures Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 82 Idorsia - Reaching out for more |
Slide 83: Consistent effect between BP measurement methodologies
Consistent effect between BP measurement methodologies Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 83 Idorsia - Reaching out for more | March 2024
Slide 84: Consistent effect among subgroups: chronic kidney disease
Consistent effect among subgroups: E.g., Patients with chronic kidney disease CKD stage 3a/b (n = 141) CKD stage 4 (n = 21) (eGFR = 30 to <60 mL/min/1.73 m2) (eGFR = 15 to <30 mL/min/1.73 m2) Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in
Slide 85: USPI Section 6: Adverse Reactions
USPI Section 6: Adverse Reactions Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 85 Idorsia - Reaching out for more | March 2024
Slide 86: Incidence of edema
Incidence of edema Returns to levels observed before randomization 8 weeks after treatment Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 86 Idorsia - Reaching out for more | M
Slide 87: USPI Section 5.2: TRYVIO REMS
USPI Section 5.2: TRYVIO REMS Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024. Market authorization is under review in other countries. 87 Idorsia - Reaching out for more | March 2024
Slide 88: Quote on providing a novel medicine
“We are eager to provide physicians and patients with a novel medicine working in a new pathway in uncontrolled hypertension that can provide additional blood pressure control” Tausif ‘Tosh’ Butt President Idorsia US Aprocitentan is only approved in the US under the tradename TRYVIO where it will be
Slide 89: Hypertension is the leading modifiable risk factor
Hypertension is the leading modifiable risk factor for early death and disability The risk of developing The importance of treating hypertension is well uncontrolled hypertension is elevated in certain 2-6x established Greater Risk subgroups of patients especially for uncontrolled Obesity Obstructiv
Slide 90: ~8M patients immediately addressable at launch
~8M patients immediately addressable at launch* – most with multiple comorbidities 3.5M Patients 4.6M Patients on 3 meds for on 4+ meds for hypertension are hypertension not controlled ~8M Immediately Addressable Patients 90% of these patients have comorbidities and are taking branded meds * in line
Slide 91: Prescribers span several specialties
Prescribers span several specialties – often more than one HCP involved 60% of Patients 50-60% of patients 30-40% of patients on 3+ Meds were treated on 3+ Meds were treated on 3+ Meds were treated by 2 or more HCPs by cardiologists and by primary care physicians nephrologists (PCPs)/other cardiolog
Slide 92: Early dialogues with Payers
Early dialogues with Payers suggest an overall favorable reaction to TRYVIO clinical profile Recognize the unmet patient need of uncontrolled hypertension Favorable reaction to Phase 3 trial design Perceive efficacy as favorable, highlighting BP differences vs placebo clinically meaningful Product a
Slide 93: Important aspects of TRYVIO for US market
Important aspects of TRYVIO for US market Easy to prescribe • One dose for all patients • No clinically relevant drug-drug interactions • Manageable side-effect profile • One-time REMS certification for HCP and Pharmacy only Easy to use • Oral once-daily tablet, with or without food • Long half-life
Slide 94: Quote on new era of endothelin research
“The approval of TRYVIO heralds a new era of endothelin research beyond hypertension, where we intend to investigate the utility of aprocitentan for first-in-class applications in new indications.” Martine Clozel Chief Scientific Officer Aprocitentan is only approved in the US under the tradename TR
Slide 95: Aprocitentan for resistant hypertension in the EU
Aprocitentan for difficult-to-control (resistant) hypertension in the EU New mode of action in systemic hypertension Current status • In January 2023, Idorsia submitted a market authorisation application (MAA) to the EMA for the treatment of patients with resistant hypertension Aprocitentan is only
Slide 96: Lucerastat in Fabry disease
Lucerastat in Fabry disease Lucerastat is investigational, in development and not approved or marketed in any country. 96 Idorsia - Reaching out for more | March 2024
Slide 97: Fabry disease
Fabry disease Fabry disease is a rare inherited lysosomal storage disorder in which a particular lipid (a fat-like substance) can’t be broken down by the body, leading to its build-up in the cells of the body organs which results in cell and organ damage Fabry disease is often undetected or misdiagn
Slide 98: What is the role of lipids in the body?
What is the role of lipids in the body? • Lipids are fat-like substances What happens in patients with lysosomal storage disorders? such as fatty acids, oils, waxes Normal breakdown of lipids and steroids. A well-known example is cholesterol • Lipids are stored naturally in the body’s cells and orga
Slide 99: Fabry disease biochemical mechanism
Fabry disease Biochemical mechanism cis-Golgi SM Dysfunctional or absent GCS α-galactosidase A Cer GlcCer Gb3 results in accumulation of Gb3 in various organs Gb3 Sph Plasma α-GalA Membrane Sph Gb3 Cer ceramide GCS glucosylceramide synthase GlcCer glucosylceramide Gb3 globotriaosylceramide lysoGb3 g
Slide 100: Inheritance pattern in Fabry disease
Inheritance pattern in Fabry disease X-linked recessive genetic disease • GLA gene mutation results in defective lysosomal enzyme α-GalA • In turn, this results in Gb3 accumulation Random X-inactivation in Fabry female ‘carriers’: both genders affected Male have generally Females have higher classic
Slide 101: Clinical manifestations of Fabry disease
Clinical manifestations of Fabry disease Large spectrum of clinical, heterogeneous manifestations Neuropathic pain Pain resulting from damage to or dysfunction Kidneys of the nervous system • Gradually progressing Cysts, reduced kidney Eyes function, progressive The appearance in severity from of th
Slide 102: Diagnosis of Fabry disease
Diagnosis of Fabry disease Clinical symptoms Clinical events Pedigree analysis Neuropathic pain, GI, Stroke, cardiac Family members hearing loss, and renal events (between children hypohydrosis and parents) Enzyme assay Genotyping Biomarkers Leukocyte α-GalA >830 mutations Gb3 in plasma and urine 10
Slide 103: Epidemiology of Fabry disease
Epidemiology of Fabry disease Patients diagnosed with Fabry disease 2018 patients, n in EU-5 and US in 2018 EU-5 3,507 UK 890 Italy 828 Germany 692 France 562 Spain 535 US 3,875 Total 7,382 Delveinsight, Fabry Disease – Market Insight, Epidemiology and Market Forecast – 2028 103 Idorsia - Reaching o
Slide 104: Current therapies in Fabry disease
Current therapies in Fabry disease No curative Symptomatic Etiological therapies limited therapy treatments not satisfactory Enzyme replacement Chaperone therapy therapy • Fabrazyme (agalsidase beta) • Galafold (migalastat) for (US and EU) patients with amenable • Replagal (agalsidase alfa) mutation
Slide 105: Lucerastat in Fabry disease
Lucerastat in Fabry disease Bioavailability Orally available, highly soluble small molecule with rapid and complete absorption Tissue penetration Access to most tissues, including peripheral and central nervous system For all mutations Potential to treat all Fabry patients irrespective of the underl
Slide 106: Lucerastat mode of action
Lucerastat in Fabry disease Mode of action lucerastat cis-Golgi SM By inhibiting GCS, GCS lucerastat reduces the Cer GlcCer Gb3 precursor of Gb3 (GlcCer) and Gb3 itself Gb3 Sph Plasma α-GalA Membrane Sph Gb3 Cer ceramide GCS glucosylceramide synthase GlcCer glucosylceramide Gb3 globotriaosylceramide
Slide 107: Lucerastat has the potential to reduce Gb3 levels in target organs
Lucerastat has the potential to reduce Gb3 levels in target organs Dorsal root Kidneys Heart ganglia *ANOVA with Bonferroni’s multiple Male and female Fabry mice treated testing correction. for 20 weeks with lucerastat at 1200 mg/kg/day as food admix and Idorsia data on file. Data collected in anima
Slide 108: Mutation sensitivity
Mutation sensitivity Proven reduction in Gb3 in all tested mutation types Effect of different concentrations of lucerastat on GlcCer, Gb3, lysoGb3 lipid levels, and LysoTracker staining in cultured Fabry patients’ fibroblasts after 9 days of treatment. Each point is the mean of duplicates (±SD) Luce
Slide 109: Lucerastat clinical development plan
Lucerastat clinical development plan • Better understand medical need from Pediatric patient perspective study Confirmatory • Plan agreed Patient survey study with EMA Exploratory • MODIFY study • MODIFY Open Label Extension Clinical pharmacology • Safety and proof of studies mechanism study • SAD a
Slide 110: Lucerastat clinical pharmacology
Lucerastat clinical pharmacology Half-life: approximately 6 hours – twice daily dosing Negligible Dose-proportional food effect exposure Dose adjustment required in Low potential subjects with renal function impairment for drug-drug interaction eGFR Dosing regimen (mL/min/1.73 m2) (mg b.i.d.) ≥ 60 1
Slide 111: Lucerastat exploratory study design
Lucerastat exploratory study design Phase 1b Prospective, single-center, open-label, randomized, study study in 14 male/female adult patients with Fabry disease receiving enzyme replacement therapy (ERT) Screening Treatment Period Follow-up + 2 Days Phone Call Admission for patients Randomization Mo
Slide 112: Lucerastat exploratory study objectives
Lucerastat exploratory study Phase 1b Primary objective study • To assess the safety and tolerability of lucerastat 1000 mg b.i.d. for 12 weeks Secondary objectives • To investigate the effect of lucerastat on plasma biomarker levels following a 12-week treatment • To assess the effect of lucerastat
Slide 113: Lucerastat exploratory study demographics
Lucerastat exploratory study Patient demographics Phase 1b study Medical history: • All patients had Lucerastat group comorbidities, most of Control group them manifestations • 6 females, 4 males of Fabry disease • 4 males • Mean age (SD): 47.7 (15.0), • None of these affected • Mean age (SD): 39.8
Slide 114: Lucerastat exploratory study safety results
Lucerastat exploratory study Safety results Phase 1b study Lucerastat was safe and well tolerated in patients with Fabry disease over 12 weeks on top of ERT One Serious Adverse Event, unrelated to lucerastat: Re-occurrence of atrial fibrillation in a patient with underlying hypertrophic cardiomyopat
Slide 115: Lucerastat exploratory study results
Lucerastat exploratory study Results: rapid and additional reduction in Gb3 when added to Phase 1b enzyme replacement therapy study Mean % (SD) biomarker reduction from baseline at week 12 Plasma Plasma Urinary Lucerastat was safe and well tolerated GB3 Gb3 GlcCer LacCer LysoGB3 in patients with F
Slide 116: Fabry patients survey
Fabry patients survey Goals Better understand Investigate key Complement patients’ disease and aspects of Phase 3 existing needs from the study MODIFY with information/data patient perspective respect to symptoms: from the literature neuropathic pain and gastrointestinal 1 symptoms 2 3 In addition,
Slide 117: Designing the confirmatory study: MODIFY
Designing the confirmatory study: MODIFY Phase 3 study MODIFY • Informed design based on patients survey • Development of endpoint measurement – neuropathic pain, based on Brief Pain Inventory instrument, modified for Fabry’s neuropathic pain according to FDA guidelines for PRO • Development and val
Slide 118: MODIFY: Objectives
MODIFY: Objectives Phase 3 study Primary objective MODIFY • To determine the effect of lucerastat on neuropathic pain in patients with Fabry disease Secondary objectives • To determine the effect of lucerastat on gastro-intestinal symptoms (abdominal pain and diarrhea) in patients with Fabry disease
Slide 119: MODIFY: Study design
MODIFY: Study design Phase 3 study MODIFY Screening 6-7 weeks Treatment 6 months Open, uncontrolled, Extension Randomization Primary/secondary 2:1 efficacy endpoints Lucerastat Placebo Site visits Stratification by Lucerastat dose Screening, Randomization, • Sex • 1000 mg b.i.d. Months 1, 2 (phone),
Slide 120: MODIFY: Patient population
MODIFY: Patient population Phase 3 study MODIFY Last ERT Randomization Switched patients ERT bi-weekly for at least 12 months (stable dose regimen during the last 3 months) Placebo Pseudo-naïve patients ERT bi-weekly No ERT in at least the last 6 months Screening period Diary card, no ERT Lucerastat
Slide 121: MODIFY: Study endpoints
MODIFY: Study endpoints Phase 3 study Primary efficacy endpoint MODIFY • The primary efficacy endpoint is a response to study treatment on neuropathic pain, defined as a reduction from baseline to Month 6 of at least 30% in the “modified” BPI-SF3 score of “neuropathic pain at its worst in the last 2
Slide 122: MODIFY: Results
MODIFY: Results Phase 3 study MODIFY • October 2021 MODIFY did not meet the primary endpoint of reducing neuropathic pain during 6 months of treatment versus placebo • Substantial and consistent reduction of plasma Gb3 – confirming the pharmacological activity of lucerastat • Based on historical pat
Slide 123: MODIFY: Open label extension study
MODIFY: Open label extension study • To determine the long-term safety and tolerability of lucerastat oral therapy and to further evaluate its clinical effects on renal and cardiac function in adult patients with Fabry disease over an additional period of up to 72 months • October 2022: Interim anal
Slide 124: Lucerastat for Fabry disease
Lucerastat for Fabry disease Glucosylceramide synthase inhibitor An oral substrate reduction therapy investigated for the treatment of adult patients with Fabry disease. • Lucerastat for Fabry disease has received orphan drug designation in the US and the EU • MODIFY did not meet the primary endpoin
Slide 125: Idorsia's other clinical development assets
Idorsia’s other clinical development assets 125 Idorsia - Reaching out for more | March 2024
Slide 126: ACT-1004-1239
ACT-1004-1239 A first-in-class, potent, selective ACKR3/CXCR7 antagonist • Preclinical data has shown both anti-inflammatory and promyelinating effects • The Phase 1 SAD and MAD studies have been completed, and following feedback from the US FDA, we are currently preparing the plan for a Phase 2 stu
Slide 127: Sinbaglustat
Sinbaglustat GBA2/GCS inhibitor • Sinbaglustat, a non-lysosomal glucosylceramidase / glucosylceramide synthase (GBA2/GCS) inhibitor, has potential for the treatment of rare lysosomal storage disorders • Following a Phase 1 clinical pharmacology program, the company ran a natural history study called
Slide 128: Other early-stage pipeline assets
Other early-stage pipeline assets • ACT-1014-6470, a C5aR1 antagonist, is currently investigated in a Phase 1 program with the target indication in immune-mediated disorders • ACT-777991, a CXCR3 antagonist, is currently investigated in a Phase 1 program with the target indication of recent-onset Ty
Slide 129: ACT-709478 (NBI-827104)
ACT-709478 (NBI-827104) A potent, selective, orally-active, and brain penetrating T-type calcium channel blocker Investigated by Neurocrine Biosciences in a Phase 2 open label extension (OLE) study for the treatment of a rare form of pediatric epilepsy known as epileptic encephalopathy with continuo
Slide 130: More knowledge – Powered by science
More knowledge – Powered by science Target selection • High medical need – patient focused • Therapeutic novelty Vaccine platform • Discovering and developing Focus on glycoconjugate vaccines small molecules • Containing synthetic antigenic • Based on organic chemistry glycan molecules • Suitable fo
Slide 131: Our drug discovery process
More joy – Transforming the horizon Our drug discovery process Preclinical Development Clinical Development Registration Launch Molecular-Biology Biochemistry (High Structural Biology (Target Finding) Throughput Screening) And Molecular Modeling Targets Hits Research Information Medicinal Management
Slide 132: Financial information FY 2022
Financial information FY 2022 132 Idorsia - Reaching out for more | March 2024
Slide 133: US GAAP net results
US GAAP net results 20 FULL YEAR in CHF millions, rounding differences may occur 22 Non-GAAP US GAAP Financial results as of Dec 31, 2022 133 Idorsia - Reaching out for more | March 2024
Slide 134: Non-GAAP operating expenses
Non-GAAP operating expenses 20 FULL YEAR in CHF millions, rounding differences may occur 22 0 -6 -112 -117 -5 0 -24 0 -250 -240 -221 -612 -854 12M 2021 -492 12M 2022 Cost of sales Research Development Milestones Inventory build SG&A Non-GAAP operating expenses Financial results as of Dec 31, 2022 13
Slide 135: Financial information 9M 2023
Financial information 9M 2023 135 Idorsia - Reaching out for more | March 2024
Slide 136: US GAAP/Non-GAAP Net Sales
US GAAP/Non-GAAP Net Sales in CHF millions, rounding differences may occur Nine Q1 Q2 Q3 months United States 3.0 5.8 6.2 15.0 Germany, Italy, Spain and 1.3 1.6 2.2 5.1 Switzerland QUVIVIQ 4.3 7.4 8.4 20.2 PIVLAZ® (Japan) 13.5 18.9 1.3 33.7 Net Sales 17.7 26.4 9.7 53.9 136 Idorsia - Reaching out for
Slide 137: Impact from Sosei deal
Impact from Sosei deal in CHF millions, rounding differences may occur Initial cash received 396 Approx. cash to be received 4 Total cash from Sosei Deal 400 Gains on sale of disposal group 302 Contract revenue from QUVIVIQ license 68 Impairment of intangible assets (7) Total profit from Sosei Deal
Slide 138: Non-GAAP operating results
Non-GAAP operating results in CHF millions, rounding differences may occur as reported proforma 131 29 -7 -4 -138 -130 -74 -74 -387 -456 -299 -277 Revenue Cost of sales Research Development SG&A Non-GAAP operating results Financial results as of September 30, 2023 138 Idorsia - Reaching out for more
Slide 139: US GAAP operating results
US GAAP operating results in CHF millions, rounding differences may occur as reported proforma 295 0 -15 -14 -27 -26 -11 -11 -145 -387 -456 -507 Non-GAAP Depreciation & Share-based Restructuring Sosei Deal US-GAAP operating Amortization compensation operating results results Financial results as of
Slide 140: Proforma Non-GAAP operating results
Proforma Non-GAAP operating results in CHF millions, rounding differences may occur 9M 2022 9M 2023 18 29 -2 -4 -148 -130 -86 -74 -456 -551 -277 -333 Revenue Cost of sales Research Development SG&A Non-GAAP operating results Financial results as of September 30, 2023 140 Idorsia - Reaching out for m
Slide 141: Proforma US GAAP operating results
Proforma US GAAP operating results in CHF millions, rounding differences may occur 9M 2022 9M 2023 -13 -14 -18 0 -11 -26 -456 -507 -551 -582 Non-GAAP Depreciation & Share-based Restructuring US-GAAP operating Amortization compensation operating results results Financial results as of September 30, 2
Slide 142: Cash flow
Cash flow in CHF millions, rounding differences may occur Financial results as of September 30, 2023 142 Idorsia - Reaching out for more | March 2024
Slide 143: Indebtedness
Indebtedness in CHF millions, rounding differences may occur *Total Indebtedness does not include conditional payments to J&J of up Financial results as of September 30, 2023 to CHF 306 m for the reacquisition of worldwide rights to aprocitentan 143 Idorsia - Reaching out for more | March 2024
Slide 144: Reacquisition of aprocitentan rights
Reacquisition of aprocitentan rights • Idorsia reacquired all worldwide rights to aprocitentan • Johnson & Johnson entitled up to CHF 306 million − If aprocitentan is approved in the US (90%) − If aprocitentan is approved in EU (10%) • Idorsia to pay J&J − 30% on aprocitentan out-license deal − 10%
Slide 145: Financial Guidance for 2023
Financial Guidance for 2023* US GAAP operating loss of around CHF 670 million and non-GAAP operating loss of around CHF 600 million *Both metrics include the restructuring charge, exclude APAC operations in 2023 until the closing of the Sosei Deal and the one-off impact of such transaction, and excl
Slide 146: Idorsia has a strong and visionary leadership team
Idorsia has a strong and visionary leadership team with the power and drive to create more remarkable innovations and more new medicines 146 Idorsia - Reaching out for more | March 2024
Slide 147: Idorsia Executive Committee
Idorsia Executive Committee Alberto Gimona Guy Braunstein André C. Muller Martine Clozel Jean-Paul Clozel Head of Global Clinical Development Chief Medical Officer Chief Financial Officer Chief Scientific Officer Chief Executive Officer 147 Idorsia - Reaching out for more | March 2024
Slide 148: Idorsia Leadership Team
Idorsia Leadership Team Kerstin Niggemann Olivier Lambert Markus Riederer Alex Khatuntsev Julien Gander Eva Caroff Andrew C. Weiss Head Pharmacological Head of Technical Head Translational Head of Global Group General Head Chemical Head of Investor Relations & Sciences Operations Sciences Human Reso
Slide 149: Be prepared for more
Be prepared for more 149 Idorsia - Reaching out for more | March 2024